Project Grant K99DA065474
- Federal Project Grant Award Summary Drexel University received a $445,636 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) on May 15, 2026, with a completion date of February 28, 2031. The award funds research investigating neural circuit mechanisms underlying inflexible drug seeking in individuals with Human Immunodeficiency Virus (HIV) infection and cocaine use disorder (CUD). The research will employ in vivo...
- Federal Project Grant Award Summary Drexel University received a $684,123 Project Grant award dated March 15, 2026, from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a cross-model investigation examining the role of inflammasomes in the neurobehavioral and transcriptomic effects of cocaine exposure and HIV infection. The research addresses a critical knowledge gap concerning the interaction between cocaine use disorder and HIV...
- Federal Project Grant Award Summary Drexel University received a $501,606 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective April 1, 2026 through January 31, 2031. The award funds preclinical research investigating hormonal and behavioral dysregulation resulting from antiretroviral exposure and chronic cocaine use in people living with HIV (PLWH) and people who use drugs (PWUD). The research employs the ECOHIV...
- Federal Grant Award Summary Drexel University received a $418,625 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop novel research addressing HIV reservoirs in the central nervous system (CNS). The award, issued July 15, 2025, with completion targeted for June 30, 2027, supports research into transcriptional silencing of HIV by long terminal repeat (LTR) targeting RNA interference (RNAi). The project focuses...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Drexel University a Project Grant totaling $832,132 under the Drug Use and Addiction Research Programs (CFDA 93.279), effective March 1, 2026, through February 29, 2028. The award supports basic neuroscience research investigating novel circuit mechanisms through which opioids elevate dopamine levels in the nucleus accumbens, a brain region critical to reward processing and addiction. Building on preliminary...
- Federal Project Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $723,388 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded May 15, 2026, with completion targeted for March 31, 2031. The award funds research investigating a novel mechanism that regulates central nervous system (CNS) viral load and HIV reservoir dynamics in the context of substance use, specifically examining...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $439,180 Project Grant effective September 1, 2025, through August 31, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279). This R21 exploratory/developmental grant supports research investigating dopaminergic neuronal-glial interactions in the striatum, with specific focus on understanding how HIV replication and methamphetamine exposure alter communication between...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Children's Hospital of Philadelphia Research Institute a $456,268 Project Grant effective March 1, 2026, through February 29, 2028, under the Drug Use and Addiction Research Programs (CFDA 93.279). This research initiative investigates antioxidant and cerebral blood flow (CBF) profiles in persons living with HIV (PWH) who use marijuana, comparing smoking versus edible consumption methods. The project employs...
- Federal Project Grant Award Summary Duke University, through its Office of Research Administration, was awarded $731,879 by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) on May 1, 2026, with a completion date of February 28, 2031. This Project Grant supports research investigating the impact of cannabis use on the NLRP3 inflammasome in people with HIV (PWH) compared to HIV-seronegative persons. The research leverages biospecimens and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA), under its Drug Use and Addiction Research Programs (CFDA 93.279), awarded Icahn School of Medicine at Mount Sinai a $2.35 million Project Grant on February 15, 2026, with completion targeted for January 31, 2030. The award funds data mining and analysis of transcriptomic sequencing datasets generated through the SCORCH (Single Cell Or Bulk RNA-seq to identify Cell Types Highly relevant to drug Abuse) consortium. The...
Grant Award Summary Drexel University received a $143,110 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective August 1, 2026 through July 31, 2028. The project, titled "Corticostriatal Glial and Peripheral Immune Mechanisms of Polysubstance Use and Associated Comorbidities," investigates the intersection of human immunodeficiency virus (HIV) infection and polysubstance use—specifically cocaine and opioid co-use—to identify novel cellular and immunological mechanisms underlying drug-seeking behavior and relapse. The research employs animal models to examine how HIV dysregulates reward learning and motivation in the striatum, with particular focus on the roles of microglia and astrocytes, as well as the independent and interactive effects of antiretroviral therapy and HIV infection on neuroimmune function. The anticipated deliverables include scientific findings on corticostriatal neural circuit dysfunction and its relationship to impaired extinction learning and reward dysregulation in the context of HIV and polysubstance use. These research outputs are intended to identify targeted treatment targets for people living with HIV who use drugs, ultimately contributing to more effective intervention strategies for substance use disorders in this vulnerable population. The work addresses a critical public health gap, given the rising overdose crisis driven by synthetic opioid co-use and the limited understanding of how multiple drugs interact to exacerbate HIV-related neurocognitive impairment in patients on antiretroviral therapy.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $143.1k | 7/17/26 |